BiotechTube
Home/Pipeline/Lacutamab (IPH4102)

Lacutamab (IPH4102)

Cutaneous T-cell Lymphoma (CTCL), Sézary Syndrome

Phase 3-readyActive, Breakthrough Therapy Designation (2025)

Key Facts

Indication
Cutaneous T-cell Lymphoma (CTCL), Sézary Syndrome
Phase
Phase 3-ready
Status
Active, Breakthrough Therapy Designation (2025)
Company
Innate Pharma, Innate Pharma

About Innate Pharma

Founded in 1999 by pioneering immunologists, Innate Pharma is a Nasdaq and Euronext-listed biotech focused on harnessing the innate immune system to fight cancer. The company has built a robust pipeline of proprietary and partnered assets, including lacutamab (anti-KIR3DL2), IPH4502 (Nectin-4 ADC), and monalizumab (anti-NKG2A, partnered with AstraZeneca). Its strategy is underpinned by strong scientific foundations, strategic collaborations with major players like AstraZeneca and Sanofi, and a leadership team with deep industry and scientific expertise.

View full company profile

About Innate Pharma

Founded in 1999 by pioneering immunologists, Innate Pharma is a Nasdaq and Euronext-listed biotech focused on harnessing the innate immune system to fight cancer. The company has built a robust pipeline of proprietary and partnered assets, including lacutamab (anti-KIR3DL2), IPH4502 (Nectin-4 ADC), and monalizumab (anti-NKG2A, partnered with AstraZeneca). Its strategy is underpinned by strong scientific foundations, strategic collaborations with major players like AstraZeneca and Sanofi, and a leadership team with deep industry and scientific expertise.

View full company profile

Therapeutic Areas

Oncology